How Will Recce’s New Hong Kong Patent Shape Asia’s Anti-Infective Market?

Broadening Intellectual Property in Asia

Recce Pharmaceuticals Limited has achieved a significant milestone with the formal granting of its Patent Family 4 in the Hong Kong Special Administrative Region. This patent, which extends protection until 2041, covers key synthetic anti-infective compounds RECCE 327 and RECCE 529. The move marks Recce’s sixth Family 4 patent, complementing existing protections in Australia, Canada, Israel, Japan, and China, and further solidifies its intellectual property portfolio across critical Asian markets.

Comprehensive Coverage of Anti-Infective Innovations

The Hong Kong patent encompasses not only the processes for preparing these novel anti-infectives but also their therapeutic applications. Notably, it validates the use of RECCE 327 and RECCE 529 in treating a broad spectrum of infections, including acute bacterial skin infections, diabetic foot infections, burn wounds, lung infections such as ventilator-associated pneumonia, urinary tract infections, gonorrhoea, influenza, and even SARS-CoV-2. The patent also covers diverse administration routes, oral, inhalation, transdermal, and injectable, offering flexibility for clinical use and patient care.

Strategic Positioning in a Growing Market

Hong Kong’s pharmaceutical market, valued at approximately US$2.5 billion and projected to grow at a compound annual growth rate of 6.5% through 2030, represents a lucrative opportunity for Recce. The patent grant enhances the company’s ability to navigate regulatory pathways and commercialise its anti-infectives in this dynamic environment. This development aligns with Recce’s ongoing Phase 3 clinical trials in Indonesia and its broader strategy to secure approvals across ASEAN countries, where demand for innovative anti-infective treatments is rising amid growing concerns over antibiotic resistance.

Leadership Perspective and Future Outlook

Recce’s CEO, James Graham, highlighted the importance of this patent as a cornerstone for expanding the company’s footprint in Asia. He emphasised that the intellectual property protection in Hong Kong not only safeguards Recce’s innovations but also enhances its capacity to introduce a new class of synthetic anti-infectives in a region with significant medical and commercial potential. With the World Health Organization recognising Recce’s compounds for their promise against priority pathogens and the US FDA granting fast-track designations, the company is well positioned to advance its pipeline.

Looking Ahead

As Recce continues to progress its clinical trials and regulatory submissions, the Hong Kong patent grant represents a pivotal step in its journey to address the global challenge of antimicrobial resistance. The company’s multi-layered approach to combating bacterial and viral infections could reshape treatment paradigms, particularly in Asia’s fast-evolving pharmaceutical landscape.